No Data
Zhejiang Garden Biopharmaceutical (300401.SZ): It is expected that the net income in 2024 will increase by 55.97%-81.96% year-on-year.
Gelonghui reported on January 13 that Zhejiang Garden Biopharmaceutical (300401.SZ) announced an expected net income of 300 million to 350 million yuan for 2024, representing a year-on-year increase of 55.97% to 81.96%. The non-recurring net income is expected to be between 250 million to 290 million yuan, which is an increase of 69.36% to 96.45% compared to the same period last year. 1. During the reporting period, the company's revenue increased by approximately 13% due to factors such as the rising selling price of Vitamin D3 products and the launch of new Vitamin A series products, while the total gross profit rose by about 10%. Among these, revenue from the Vitamins sector increased by approximately 55%.
Garden Biology: 2024 Annual Results Forecast
Zhejiang Garden Biopharmaceutical (300401.SZ): Plans to establish a subsidiary in Macau to engage in the research, production, and sales of health-related products.
On December 31, Gelonghui reported that Zhejiang Garden Biopharmaceutical (300401.SZ) announced plans to establish a subsidiary in Macau to expand its domestic and international markets and enhance the company's brand influence and market competitiveness. The establishment of a subsidiary in Macau aims to leverage Macau's international platform, expand both domestic and overseas markets, and enhance the company's brand influence and market competitiveness. Additionally, Macau has a solid industrial foundation and favorable policy environment for the research and development, production, and sales of big health products, which is beneficial for the company's big health business development.
Potential Upside For Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) Not Without Risk
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 4.8% Last Week
Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical has obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.
On November 22, Glonghui reported that zhejiang garden biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary zhejiang garden pharmaceutical co., ltd. (hereinafter referred to as "garden pharmaceutical") recently received the "pharmaceutical registration certificate" for alendronate sodium tablets approved by the National Medical Products Administration. Alendronate sodium tablets are primarily used to treat osteoporosis in postmenopausal women and male osteoporosis to increase bone mass. Alendronate sodium tablets are classified as Category B drugs in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Directory (2023)."
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Shares May Have Run Too Fast Too Soon
No Data
